Abu Dhabi Recognises Abu Dhabi Stem Cells Center (ADSCC) as a Centre of Excellence in Hematopoietic Stem Cell Transplantation

By HEOR Staff Writer

April 5, 2023

Abu Dhabi Stem Cells Center (ADSCC), a subsidiary of PureHealth, has been named a centre of excellence in Hematopoietic Stem Cell Transplantation by the Department of Health – Abu Dhabi. The centre provides specialised and distinguished programmes with a high level of expertise and multidisciplinary resources, allowing it to conduct advanced medical procedures in specific clinical areas and conducting complex researches to provide the highest levels of care. The centre will provide an integrated and specialised range of surgical and non-surgical clinical services with world-class healthcare quality for patients who require hematopoietic stem cell transplantation for the treatment of blood diseases. To date, 13 cancer patients and one MS female patient have been treated by ADSCC under the AD-BMT programme.

Reference url

Recent Posts

Advancements in Pulsed Field Ablation: The VARIPULSE Pro Platform Launch

By HEOR Staff Writer

April 9, 2026

Johnson & Johnson’s launchs the VARIPULSE Pro Platform in Europe. Pulsed field ablation has advanced significantly with the introduction of a new pulse sequence that delivers ablation lesions five times faster than the previous version while maintaining equivalent lesion quality and the estab...
Antimicrobial Resistance Art: Bridging Science and Health Through Visual Storytelling

By João L. Carapinha

Antimicrobial resistance art is powerfully demonstrated in the illustrated album Sketching Antimicrobial Resistance: Thirty Stories, One Health, published in November 2025 by the EU-JAMRAI 2 initiative. The publication brings together 30 original artworks from artists across 30 European ...
Differentiated Visceral Fat Reduction in Early Trials of WVE-007

By João L. Carapinha

April 7, 2026

New clinical evidence shows meaningful visceral fat reduction with a single dose of an investigational therapy. A single 240 mg dose of WVE-007, an investigational INHBE GalNAc-siRNA (SpiNA design), produced continued placebo-adjusted reductions in visceral fat mass (−14.3%; p<0.05) and total ...